Cipla launches Roche's Covid antibody cocktail in India for Rs 60k per dose

The antibody cocktail (Casirivimab and Imdevimab) is to be administered for the treatment of mild to moderate Covid-19 in adults and pediatric patients

Swiss multinational drug firm Roche’s antibody cocktail (Casrivimab and Imdevimab) is now available in India, its marketing partner here Cipla said on Monday.

The first batch of this therapy is now available, the firm said, and the second batch will be available by mid-June. “In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offer treatment for two patients,” Cipla said.

The price for each patient dose [a combined dose of 1200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs 59,750 inclusive of all taxes.